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90 Poster Session-I(p 5 0.04) and higher HLA disparity (p 5 0.04). Variables not
associated with CMV reactivation were gender, disease risk
(standard vs. high), conditioning regimen, and cell doses defined as
total nucleated, CD34 or CD3 cell dose. No factor was associated
with CMV reactivation in multivariate analysis. CMV reactivation
did not impact incidence of TRM (p 5 0.88), relapse (p 5 0.62) or
survival (p 5 0.78). Likewise, CMV reactivation was not associated
with risk of acute or chronic GVHD. In summary, this analysis,
the largest study to date on CMV reactivation in UCBT patients,
suggests that CMV reactivation is similar to that reported for other
HSC sources and has little demonstrable impact on transplant out-
comes. Perhaps, current CMV prophylaxis and treatment strategies
have marginalized the historical significance of CMV in recipients of
allogeneic HSC.247
PALIFERMIN FOR PREVENTION OF ORAL MUCOSITIS (OM) IN ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) USING A FRAC-
TIONATED TOTAL BODY IRRADIATION (FTBI)-BASED CONDITIONING
REGIMEN
Shayani, S.1, Spielberger, R.T.2, Tsai, N.-C.3, Palmer, J.3, Chau, S.1,
Forman, S.J.2 1City of Hope; 2City of Hope; 3City of Hope, Duarte, CA
OM is a complication of myeloablative therapy followed by
HSCT. Severe OM in patients (pts) undergoing HSCT with
a FTBI-based conditioning regimen has been reported in up to
80% of pts (Woo et al. Cancer 1993; 72). Palifermin, (PAL, Kepiv-
ance), a recombinant human keratinocyte growth factor, has been
shown to reduce the duration and severity of OM in pts undergoing
FTBI-based conditioning regimen prior to autologous HSCT
(Spielberger et al. NEJM 2004; 351). Benefits of PAL in pts under-
going allogeneic (Allo) HSCT from a related or a matched unrelated
donor were evaluated in a comparative, retrospective study. Data on
a cohort of pts who received PAL (N 5 33) were compared to a co-
hort of pts who did not (Control: N 5 31). Conditioning regimen
consisted of FTBI and etoposide. OM was defined as ‘‘Mild’’ and
‘‘Severe’’ based on CTC v2.0 (Mild 5 grades 1 and 2, Severe 5
grades 3 and 4). Baseline characteristics for both cohorts were not
statistically different in respect to gender, diagnosis, disease status,
GVHD prophylaxis regimen, type of donor, and stem cell source.
Median age was lower for pts in the control group (44 vs. 34 years,
P 5 0.01). All pts developed OM with a median duration of 15
days for the PAL cohort and 20 days for the control (P5 0.05). Over-
all incidence of severe OM by univariate analysis was 55% and 81%
for pts in the PAL and control groups, respectively (P 5 0.03). Me-
dian duration of severe OM among all pts was 2 days (0–28) for those
who received PAL and 5 days (0–16) for pts who did not (P5 0.007).
Patients in the PAL group received intensive oral care (delivered by
certified respiratory therapists) for 11 days (0–30) vs. 15 days (0–47)
for pts in the control group (P5 0.02). Median opioid analgesic use
attributed to mucositis pain (in morphine equivalents) was 542 (47–
6330) mg and 837 (225–18137) mg for PAL and control groups (P5
0.14). Cumulative incidence of acute GVHD grades III and IV was
9% for pts in PAL group and 29% for the control (P5 0.05). Overall
probability of 100-day survival for PAL and control cohorts was
93.9% and 77.4% (P 5 0.06). No clinically significant differences
were observed in duration of TPN use, length of hospital stay, or
ICU admissions. When compared, use of methotrexate did not im-
pact the outcomes.
Conclusions: Results suggests that PAL reduced the incidence of
severe OM and the duration of all grades of OM, as well as reducing
the health resource utilization for prevention and treatment of OM
in pts undergoing Allo HSCT.248
COST ANALYSIS OF MOBILIZATION AND AUTOLGOUS TRANSPLANTA-
TION IN PATIENTSWHORECEIVED AMD3100 AFTER FAILING STANDARD
MOBILIZATION
Delgado, E.1, LeMaistre, C.F.1, Bachier, C.1, Smith, B.2, Lopez-
Gonzalez, G.1, Hougham, M.1, Kaleel, S.1, Shaughnessy, P.1 1Texas
Transplant Institute, San Antonio, TX; 2Altarum, San Antonio, TX
This retrospective study evaluated the difference in clinical out-
comes and costs of mobilization and transplant between pts whoachieved sufficient CD341 cells to proceed to transplant using
a standard mobilization regimen (control group) versus pts who
had failed previous mobilization regimens and were remobilized
with AMD3100 and G-CSF in the compassionate use protocol
(CUP). A total of 88 pts in the control group and 36 pts in CUP
were evaluated. Following AMD3100 administration, 33 (94%) pts
achieved successful mobilization of .2 million/kg CD341 cells. A
median of 3.36 106 CD341 cells/kg (range, 0.51–13.05) were col-
lected in a median of 3 (range, 1–4) apheresis days. In comparison,
control pts collected a median of 10.8 106 CD341 cells/kg (range,
1.95–69.32) in a median of 2 (range, 1–6) apheresis days. Twenty-
eight CUP pts went on to transplant and had a median day to
ANC . 500/ml of 11 days (range, 9–17) and platelets .20,000 /ml
of 27 days (range, 13–37). At day 100, 92% of the CUP pts reached
engraftment and there were no transplant related mortalities. The
control population had a median day to ANC .500/ul of 11 days
(range, 8–14) and platelets .20,000/ml of 18 days (range, 9–83).
The control group experienced 100% engraftment and one trans-
plant related fatality. Relapse occurred in 14% of the CUP pts and
32 % of the control pts. The median cost of remobilization with
AMD3100 was $2,959 less in the CUP pts than the median cost of
initial mobilization for the control group, but this was not signifi-
cantly different between the groups. The median total cost of mobi-
lization in the CUP pts, including initial mobilization costs, was
$16,927 more than in the control pts (p\0.0001). In both groups
of pts greater than 95% of total transplant costs occurred in the first
30 days of the transplant course. The difference in the total median
transplant costs at day 30 in the CUPpts was $7,373more than in the
control pts. (p 5 0.0024). CUP pts incurred 91% of total costs and
control pts 57% of total costs in the first 30 days. In conclusion, re-
mobilization with AMD31001G-CSF allowed a high percentage of
patients who failed standard mobilization to subsequently mobilize
adequate CD341 cells and proceed to autologous transplant with
acceptable clinical outcomes. Pts who required remobilization also
had an increased cost of transplantation because of increased inpa-
tient costs.249
HIGHER COSTS OF UMBILICAL CORD BLOOD (UCB) TRANSPLANTATION
COMPARED TO HEMATOPOIETIC CELL TRANSPLANTATION (HCT) USING
MATCHED RELATED DONORS (MRD): INFLUENCE OF ENGRAFTMENT
AND POST-HCT COMPLICATIONS
Majhail, N.S., Mothukuri, J.M., Brunstein, C.G., Weisdorf, D.J. Uni-
versity of Minnesota, Minneapolis, MN
Allogeneic HCT is a complex, resource intense and costly proce-
dure. UCB is an alternative graft source for patients without MRD;
however, costs of UCB HCT have not been described. We com-
pared the costs of HCT within the first 100 days among consecutive
adult patients (age$18 years) who receivedMRD (N5 130) orUCB
(N 5 164) HCT from 2004–2006. Patients received either myeloa-
blative (MA; MRD 5 67, UCB 5 63) or non-myeloablative (NMA;
MRD5 54, UCB5 110) conditioning. The four groups were com-
parable except for a higher proportion of young (age# 50 years) re-
cipients among MA regimens and HLA mismatched grafts among
UCB recipients. Cumulative incidence of graft failure was signifi-
cantly higher among UCB recipients (MA MRD 3%, MA UCB
19%, NMA MRD 0%, NMA UCB 8% [p\ 0.01]), as was the me-
dian time to neutrophil engraftment (17 days, 23 days, 7 days, 13
days [p \ 0.01]). The 100-day probabilities of overall survival
(81%, 70%, 78%, 78% [P 5 0.95]) and cumulative incidence of
TRM (21%, 29%, 20%, 19% [P 5 0.55]) were comparable. Cumu-
lative incidence of acute severeGVHDand rates of major post-HCT
complications (dialysis, mechanical ventilation and hepatic veno-oc-
clusive disease) were also similar. The median cost per day survived
(excluding costs of graft acquisition) was $1016 (interquartile range
[IQR] 796–2232) for MA MRD, $2082 (IQR 1306–6219) for MA
UCB, $612 (IQR 473–1023) for NMA MRD and $1156 (IQR
616–2472) for NMA UCB recipients, respectively (p\ 0.001). For
all groups, room-board and pharmacy services were the major con-
tributors to totals costs of HCT. In multivariate analysis adjusting
for important patient, disease and HCT related characteristics as
well as major post-HCT complications, significant predictors for
higher costs within the first 100 days after HCT were MA UCB
HCT, graft failure, need for dialysis or mechanical ventilation and
